Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. Lin BioScience, Inc. is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does Lin BioScience Inc. (6696) operate in?
Lin BioScience Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Lin BioScience Inc. (6696) current stock price?
As of the latest data, Lin BioScience Inc. stock price is NT$881.00, with a previous close of NT$881.00.
What is Lin BioScience Inc. (6696) current market capitalization?
Lin BioScience Inc. market cap is approximately 730.53 billion.
What is Lin BioScience Inc. (6696) Earnings Per Share (EPS)?
The trailing EPS is -NT$16.57.
Does Lin BioScience Inc. (6696) pay dividends?
No. Lin BioScience Inc. does not pay a dividend.
What is Lin BioScience Inc. (6696) beta (volatility) score?
Lin BioScience Inc. has a beta of 0.161, indicating lower volatility than the overall market.
